Ranking
Most Affordable Tirzepatide Programs
Affordability is measured here as the effective monthly cost of continuing treatment, because SURMOUNT-4 showed that stopping produces substantial regain. A program that is cheap for one month and expensive thereafter is not affordable. Only records where mandatory fees are confirmed are ranked; every exclusion is published with its reason.
Key takeaways
- Affordability is judged on sustained recurring cost, not first-month or introductory pricing.
- SURMOUNT-4 evidence means the realistic planning horizon is years, not weeks.
- Only like-for-like records are ranked; fee-unknown records are excluded and listed.
- Committed multi-month tiers lower the monthly rate but increase the amount at risk if you stop.
- Dose-related surcharges are unverified for most providers and could change the real figure.
| Criterion | Normalised effective monthly cost at a maintenance-dose scenario |
|---|---|
| Records reviewed | 24 |
| Eligible | 5 |
| Excluded | 19 |
| Ordering | Computed cost only — no editorial score |
| Methodology | v1.0 |
| Publisher relationship with providers | None |
Which providers rank highest?
| # | Provider | Effective $/mo | Basis | Mandatory fees | Price verified |
|---|---|---|---|---|---|
| 1 | TRYM Health | $125 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | No hidden membership/shipping fees advertised | 2026-07-20 |
| 2 | NexLife | $186 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | No separate membership fee; consultations and expedited shipping adver | 2026-07-20 |
| 3 | Fridays | $240 | advertised monthly rate with medication included and no separate membership fee | Generally advertised as all-inclusive | 2026-07-20 |
| 4 | Mochi Health | $278 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | Membership $39 first month, then $79/month; shipping advertised includ | 2026-07-20 |
| 5 | Eden | $298 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | Membership separate | 2026-07-20 |
What time horizon should affordability be judged over?
Years, not months. SURMOUNT-4 randomised people who had already lost weight on tirzepatide to continue or stop, and the group that stopped regained substantially. If maintaining the result generally requires continued treatment, then a first-month discount is close to irrelevant and the recurring price is nearly everything.
That reframing changes the ranking. A program with a low introductory rate and a high renewal price can cost far more over two years than one with a flat, slightly higher published rate.
What does a full year actually cost?
| Provider | Effective $/mo | 12-month cost | 24-month cost |
|---|---|---|---|
| TRYM Health | $125 | $1,500 | $3,000 |
| NexLife | $186 | $2,232 | $4,464 |
| Fridays | $240 | $2,880 | $5,760 |
| Mochi Health | $278 | $3,336 | $6,672 |
| Eden | $298 | $3,576 | $7,152 |
- Assumes the recurring price does not change and no dose surcharge applies — neither is verified for most providers.
- Excludes any cost of laboratory work, follow-up visits, or treatment of side effects.
- Committed tiers may be non-refundable; cancellation terms are unverified.
What was the sample, and what was excluded?
Sample: 24 provider records reviewed, 5 eligible for this category, 19 excluded. Methodology v1.0; each record carries its own price-verification date.
| Provider | Reason for exclusion |
|---|---|
| OrderlyMeds | Advertised as a “from” starting price, not a recurring all-in cost |
| Henry Meds | Price stated in free text that cannot be normalised |
| Ivím Health | Price stated in free text that cannot be normalised |
| Amble | Price stated in free text that cannot be normalised |
| Lavender Sky Health | Advertised as a “from” starting price, not a recurring all-in cost |
| Fifty 410 | Advertised as a “from” starting price, not a recurring all-in cost |
| ShedRx / SHED | Advertised as a “from” starting price, not a recurring all-in cost |
| Remedy Meds | Mandatory-fee inclusion not confirmed in the captured source |
| Willow | Advertised as a “from” starting price, not a recurring all-in cost |
| GobyMeds | Price stated in free text that cannot be normalised |
| Zappy Health | Price stated in free text that cannot be normalised |
| SlimDownRx | Price stated in free text that cannot be normalised |
| Valhalla Vitality | Price stated in free text that cannot be normalised |
| Hims & Hers | Advertised figure covers medication only; mandatory care or membership fees billed separately |
| Ro Body | Price stated in free text that cannot be normalised |
| WeightWatchers Clinic | Advertised figure covers medication only; mandatory care or membership fees billed separately |
| Noom Med | Price stated in free text that cannot be normalised |
| LifeMD | Advertised as a “from” starting price, not a recurring all-in cost |
| Found | Advertised as a “from” starting price, not a recurring all-in cost |
How this ranking was produced
One shared eligibility function governs every ranking on this site: a record qualifies only when a recurring tirzepatide cost can be computed on a like-for-like basis, meaning mandatory fees are either included or confirmed absent. Ordering is by computed cost alone, with no editorial score.
The full methodology, including every exclusion rule, is published on the main provider ranking. Records excluded from this category are listed below with the reason each was excluded.
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
How does affordability differ from price?
Price is a number attached to a transaction. Affordability is whether a person can sustain that number for as long as the treatment needs to continue, which introduces variables price alone ignores: income stability, the size of any prepayment, and what happens financially if treatment must stop.
A twelve-month prepaid plan at a low monthly rate can be the least affordable option available to someone whose circumstances might change, because it converts a recurring decision into a single large commitment. Affordability in that sense favours flexibility, which is why the month-to-month figures are shown alongside the committed rates throughout this site rather than buried.
How sensitive is this ranking to its own assumptions?
A ranking that changes order when a single assumption moves is fragile, and a reader deserves to know which assumptions are load-bearing. The table below re-runs the ordering under three alternative assumptions to show which conclusions survive and which do not. This is the analysis most commercial comparison sites omit, because a ranking that visibly depends on its own choices is harder to present as authoritative.
| Provider | Committed monthly | Month-to-month | Committed year | Flexible year |
|---|---|---|---|---|
| TRYM Health | $125 | $180 | $1,500 | $2,160 |
| NexLife | $186 | $215 | $2,232 | $2,580 |
| Fridays | $240 | $240 | $2,880 | $2,880 |
| Mochi Health | $278 | $278 | $3,336 | $3,336 |
| Eden | $298 | $298 | $3,576 | $3,576 |
The ordering is stable across both assumptions in the current dataset: TRYM Health is lowest whether the comparison uses committed pricing or month-to-month pricing. That stability matters because it means the leading position does not depend on a reader accepting a long prepayment. Where a ranking only holds under a twelve-month commitment, the commitment is doing the work rather than the price, and this site would say so.
What happens to this ranking when the excluded records are resolved?
19 of 24 records are currently outside the ranked set. That is a large proportion, and it would be misleading to present the ranked table as a picture of the whole market without saying what the excluded records might do to it. Each exclusion category resolves differently.
| Exclusion category | Count | Providers | How it would resolve |
|---|---|---|---|
| From Teaser | 7 | OrderlyMeds, Lavender Sky Health, Fifty 410, ShedRx / SHED, Willow, LifeMD, Found | These providers advertise a starting price. Resolution requires confirming what the same programme costs at a standard maintenance dose on a recurring basis. Historically, resolved 'from' prices land materially above the |
| Not Normalisable | 9 | Henry Meds, Ivím Health, Amble, GobyMeds, Zappy Health, SlimDownRx, Valhalla Vitality, Ro Body, Noom Med | These providers publish pricing in a form that cannot be reduced to a recurring monthly figure at all. Resolution requires a direct written quotation. |
| Fee Unknown | 1 | Remedy Meds | These providers state a monthly figure without confirming whether mandatory fees are included. Resolution could move them in either direction, which is precisely why they are not ranked on an assumption. |
| Medication Only | 2 | Hims & Hers, WeightWatchers Clinic | These providers quote medication separately from a care or membership charge. Resolution requires the sum. Because the separate charge is recurring, the resolved figure is necessarily higher than the advertised one. |
The honest summary is that the ranked set is a floor rather than a complete market picture. It shows the providers whose costs can currently be compared, ordered correctly. It does not show that no cheaper option exists anywhere — it shows that no cheaper option has published enough information to be verified. Those are different claims, and conflating them is the most common failure in this category.
What should you verify before acting on any ranking?
A ranking is a starting point built from public information at a moment in time. These checks convert it into a decision you can rely on.
- Confirm the recurring price on the provider's own checkout, not on its marketing page.
- Ask what the price becomes after any introductory period ends.
- Get a complete list of mandatory fees in writing.
- Ask what the price becomes at 10 mg and 15 mg.
- Ask which pharmacy compounds the medication and confirm its licence with the state board.
- Read the cancellation terms before prepaying for any multi-month plan.
- Check the price-verification date on this page against today's date.
If a provider's answers differ from what is published here, that is a correction this site wants. Submit it with the documentation and the record will be updated with a dated note.
What does this page cover, and what does it deliberately leave out?
This page addresses Normalized costs, maintenance-dose scenario and sample and exclusions, organised around the primary question of most affordable tirzepatide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Normalized costs | Covered on this page | Captured record |
| Maintenance-dose scenario | Covered on this page | Captured record |
| Sample and exclusions | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with each provider's own checkout |
What are the limits of what this page can tell you?
Every page on this site rests on a specific ranking methodology and its inputs, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for each provider's own checkout.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on most affordable tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 6 technical terms this page uses, including 503A, 503B, DOI, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
Frequently asked questions
What is the most affordable tirzepatide program?
Judged on sustained recurring cost rather than introductory pricing, the ranking above orders eligible records. Affordability over years is the relevant test.
Why judge affordability over two years?
Because SURMOUNT-4 showed stopping produces substantial regain, so treatment is realistically ongoing. A first-month discount is close to irrelevant against that horizon.
Do committed tiers make treatment more affordable?
They lower the monthly rate but increase the amount at risk if you stop early, and cancellation terms are unverified across the dataset.
What costs are missing from these figures?
Laboratory work, follow-up visits, treatment of side effects, and any dose-related surcharge.
Is brand medication ever more affordable?
With insurance coverage or manufacturer cash-pay eligibility it can be — see cost without insurance.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.